A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A–Related Acute Liver Failure

Jin Dong Kim; Eun Ju Cho; Choonghyun Ahn; Sue K. Park; Jong Young Choi; Han Chu Lee; Do Young Kim; Moon Seok Choi; Hee Jung Wang; In Hee Kim; Jong Eun Yeon; Yeon Seok Seo; Won Young Tak; Moon Young Kim; Heon Ju Lee; Yun Soo Kim; Dae Won Jun; Joo Hyun Sohn; So Young Kwon; Sang Hoon Park; Jeong Heo; Sook Hyang Jeong; Jeong Hoon Lee; Nobuaki Nakayama; Satoshi Mochida; Akio Ido; Hirohito Tsubouchi; Hazime Takikawa; Shalimar; Subrat Kumar Acharya; William Bernal; John O’Grady; Yoon Jun Kim

doi:10.1002/hep.30262

A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A–Related Acute Liver Failure

Jin Dong Kim, Eun Ju Cho, Choonghyun Ahn, Sue K. Park, Jong Young Choi, Han Chu Lee, Do Young Kim, Moon Seok Choi, Hee Jung Wang, In Hee Kim, Jong Eun Yeon, Yeon Seok Seo, Won Young Tak, Moon Young Kim, Heon Ju Lee, Yun Soo Kim, Dae Won Jun, Joo Hyun Sohn, So Young Kwon, Sang Hoon ParkJeong Heo, Sook Hyang Jeong, Jeong Hoon Lee, Nobuaki Nakayama, Satoshi Mochida, Akio Ido, Hirohito Tsubouchi, Hazime Takikawa, Shalimar, Subrat Kumar Acharya, William Bernal, John O’Grady, Yoon Jun Kim

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

Acute liver failure (ALF) caused by hepatitis A is a rare but fatal disease. Here, we developed a model to predict outcome in patients with ALF caused by hepatitis A. The derivation set consisted of 294 patients diagnosed with hepatitis A–related ALF (ALFA) from Korea, and a validation set of 56 patients from Japan, India, and United Kingdom. Using a multivariate proportional hazard model, a risk-prediction model (ALFA score) consisting of age, international normalized ratio, bilirubin, ammonia, creatinine, and hemoglobin levels acquired on the day of ALF diagnosis was developed. The ALFA score showed the highest discrimination in the prediction of liver transplant or death at 1 month (c-statistic, 0.87; 95% confidence interval [CI], 0.84-0.92) versus King’s College criteria (KCC; c-statistic, 0.56; 95% CI, 0.53-0.59), U.S. Acute Liver Failure Study Group index specific for hepatitis A virus (HAV-ALFSG; c-statistic, 0.70; 95% CI, 0.65-0.76), the new ALFSG index (c-statistic, 0.79; 95% CI, 0.74-0.84), Model for End-Stage Liver Disease (MELD; c-statistic, 0.79; 95% CI, 0.74-0.84), and MELD including sodium (MELD-Na; c-statistic, 0.78; 95% CI, 0.73-0.84) in the derivation set (all P < 0.01). In the validation set, the performance of the ALFA score (c-statistic, 0.84; 95% CI, 0.74-0.94) was significantly better than that of KCC (c-statistic, 0.65; 95% CI, 0.52-0.79), MELD (c-statistic, 0.74; 95% CI, 0.61-0.87), and MELD-Na (c-statistic, 0.72; 95% CI, 0.58-0.85) (all P < 0.05), and better, but not statistically significant, than that of the HAV-ALFSG (c-statistic, 0.76; 95% CI, 0.61-0.90; P = 0.28) and new ALFSG indices (c-statistic, 0.79; 95% CI, 0.65-0.93; P = 0.41). The model was well-calibrated in both sets. Conclusion: Our disease-specific score provides refined prediction of outcome in patients with ALF caused by hepatitis A.

Original language	English
Pages (from-to)	621-629
Number of pages	9
Journal	Hepatology
Volume	70
Issue number	2
DOIs	https://doi.org/10.1002/hep.30262
Publication status	Published - 2019 Aug

Bibliographical note

Funding Information:
Received February 7, 2018; accepted August 20, 2018. Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.30262/suppinfo. Supported by a grant from the Korean Association for the Study of the Liver. *These authors contributed equally to this work. © 2018 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.30262 Potential conflict of interest: Dr. Mochida is on the speakers’ bureau and received grants from AbbVie GK, Bristol-Myers Squibb, Toray, MSD K.K., and Sumitomo Dainippon. He is on the speakers’ bureau for Ajinomoto and Gilead. He received grants from A2 Healthcare, Chugai, and Eisai.

Funding Information:
The authors extend their gratitude to the investigators in each center who participated in this study: Dong Hyun Lee, Seung Hyun Ma (Seoul National University); Hee Yeon Kim, Jung Min Bae (Catholic University); Nae-Yun Heo (Inje University); Chang Hyeon Seock, Jihyun An (University of Ulsan); Hana Park, Mi Na Kim (CHA University); Jin Hee Lee, Won Sohn, Ju-Yeon Cho (Sungkyunkwan University); Weiguang Xu (Ajou?University); Chang Hun Lee (Chonbuk National University); Yang Jae Yoo, Chang Ho Jung (Korea?University); Young Oh Kweon, Yu Rim Lee (Kyungpook National University); Soon Koo Baik (Yonsei?University); Jae Young Lee (Yeungnam?University); Oh Sang Kwon, Hyunhwa Yoon (Gachon University); Ki Deok Yoo, Tae?Yeob Kim (Hanyang University); and Hyun Young Woo (Pusan National University).

Publisher Copyright:
© 2018 by the American Association for the Study of Liver Diseases.

All Science Journal Classification (ASJC) codes

Hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hep.30262

Cite this

Kim, J. D., Cho, E. J., Ahn, C., Park, S. K., Choi, J. Y., Lee, H. C., Kim, D. Y., Choi, M. S., Wang, H. J., Kim, I. H., Yeon, J. E., Seo, Y. S., Tak, W. Y., Kim, M. Y., Lee, H. J., Kim, Y. S., Jun, D. W., Sohn, J. H., Kwon, S. Y., ... Kim, Y. J. (2019). A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A–Related Acute Liver Failure. Hepatology, 70(2), 621-629. https://doi.org/10.1002/hep.30262

@article{2da60a81f1df4c198300d743f8631803,

title = "A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A–Related Acute Liver Failure",

abstract = "Acute liver failure (ALF) caused by hepatitis A is a rare but fatal disease. Here, we developed a model to predict outcome in patients with ALF caused by hepatitis A. The derivation set consisted of 294 patients diagnosed with hepatitis A–related ALF (ALFA) from Korea, and a validation set of 56 patients from Japan, India, and United Kingdom. Using a multivariate proportional hazard model, a risk-prediction model (ALFA score) consisting of age, international normalized ratio, bilirubin, ammonia, creatinine, and hemoglobin levels acquired on the day of ALF diagnosis was developed. The ALFA score showed the highest discrimination in the prediction of liver transplant or death at 1 month (c-statistic, 0.87; 95% confidence interval [CI], 0.84-0.92) versus King{\textquoteright}s College criteria (KCC; c-statistic, 0.56; 95% CI, 0.53-0.59), U.S. Acute Liver Failure Study Group index specific for hepatitis A virus (HAV-ALFSG; c-statistic, 0.70; 95% CI, 0.65-0.76), the new ALFSG index (c-statistic, 0.79; 95% CI, 0.74-0.84), Model for End-Stage Liver Disease (MELD; c-statistic, 0.79; 95% CI, 0.74-0.84), and MELD including sodium (MELD-Na; c-statistic, 0.78; 95% CI, 0.73-0.84) in the derivation set (all P < 0.01). In the validation set, the performance of the ALFA score (c-statistic, 0.84; 95% CI, 0.74-0.94) was significantly better than that of KCC (c-statistic, 0.65; 95% CI, 0.52-0.79), MELD (c-statistic, 0.74; 95% CI, 0.61-0.87), and MELD-Na (c-statistic, 0.72; 95% CI, 0.58-0.85) (all P < 0.05), and better, but not statistically significant, than that of the HAV-ALFSG (c-statistic, 0.76; 95% CI, 0.61-0.90; P = 0.28) and new ALFSG indices (c-statistic, 0.79; 95% CI, 0.65-0.93; P = 0.41). The model was well-calibrated in both sets. Conclusion: Our disease-specific score provides refined prediction of outcome in patients with ALF caused by hepatitis A.",

author = "Kim, {Jin Dong} and Cho, {Eun Ju} and Choonghyun Ahn and Park, {Sue K.} and Choi, {Jong Young} and Lee, {Han Chu} and Kim, {Do Young} and Choi, {Moon Seok} and Wang, {Hee Jung} and Kim, {In Hee} and Yeon, {Jong Eun} and Seo, {Yeon Seok} and Tak, {Won Young} and Kim, {Moon Young} and Lee, {Heon Ju} and Kim, {Yun Soo} and Jun, {Dae Won} and Sohn, {Joo Hyun} and Kwon, {So Young} and Park, {Sang Hoon} and Jeong Heo and Jeong, {Sook Hyang} and Lee, {Jeong Hoon} and Nobuaki Nakayama and Satoshi Mochida and Akio Ido and Hirohito Tsubouchi and Hazime Takikawa and Shalimar and Acharya, {Subrat Kumar} and William Bernal and John O{\textquoteright}Grady and Kim, {Yoon Jun}",

note = "Funding Information: Received February 7, 2018; accepted August 20, 2018. Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.30262/suppinfo. Supported by a grant from the Korean Association for the Study of the Liver. *These authors contributed equally to this work. {\textcopyright} 2018 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.30262 Potential conflict of interest: Dr. Mochida is on the speakers{\textquoteright} bureau and received grants from AbbVie GK, Bristol-Myers Squibb, Toray, MSD K.K., and Sumitomo Dainippon. He is on the speakers{\textquoteright} bureau for Ajinomoto and Gilead. He received grants from A2 Healthcare, Chugai, and Eisai. Funding Information: The authors extend their gratitude to the investigators in each center who participated in this study: Dong Hyun Lee, Seung Hyun Ma (Seoul National University); Hee Yeon Kim, Jung Min Bae (Catholic University); Nae-Yun Heo (Inje University); Chang Hyeon Seock, Jihyun An (University of Ulsan); Hana Park, Mi Na Kim (CHA University); Jin Hee Lee, Won Sohn, Ju-Yeon Cho (Sungkyunkwan University); Weiguang Xu (Ajou?University); Chang Hun Lee (Chonbuk National University); Yang Jae Yoo, Chang Ho Jung (Korea?University); Young Oh Kweon, Yu Rim Lee (Kyungpook National University); Soon Koo Baik (Yonsei?University); Jae Young Lee (Yeungnam?University); Oh Sang Kwon, Hyunhwa Yoon (Gachon University); Ki Deok Yoo, Tae?Yeob Kim (Hanyang University); and Hyun Young Woo (Pusan National University). Publisher Copyright: {\textcopyright} 2018 by the American Association for the Study of Liver Diseases.",

year = "2019",

month = aug,

doi = "10.1002/hep.30262",

language = "English",

volume = "70",

pages = "621--629",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "2",

}

Kim, JD, Cho, EJ, Ahn, C, Park, SK, Choi, JY, Lee, HC, Kim, DY, Choi, MS, Wang, HJ, Kim, IH, Yeon, JE, Seo, YS, Tak, WY, Kim, MY, Lee, HJ, Kim, YS, Jun, DW, Sohn, JH, Kwon, SY, Park, SH, Heo, J, Jeong, SH, Lee, JH, Nakayama, N, Mochida, S, Ido, A, Tsubouchi, H, Takikawa, H, Shalimar, Acharya, SK, Bernal, W, O’Grady, J & Kim, YJ 2019, 'A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A–Related Acute Liver Failure', Hepatology, vol. 70, no. 2, pp. 621-629. https://doi.org/10.1002/hep.30262

TY - JOUR

T1 - A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A–Related Acute Liver Failure

AU - Kim, Jin Dong

AU - Cho, Eun Ju

AU - Ahn, Choonghyun

AU - Park, Sue K.

AU - Choi, Jong Young

AU - Lee, Han Chu

AU - Kim, Do Young

AU - Choi, Moon Seok

AU - Wang, Hee Jung

AU - Kim, In Hee

AU - Yeon, Jong Eun

AU - Seo, Yeon Seok

AU - Tak, Won Young

AU - Kim, Moon Young

AU - Lee, Heon Ju

AU - Kim, Yun Soo

AU - Jun, Dae Won

AU - Sohn, Joo Hyun

AU - Kwon, So Young

AU - Park, Sang Hoon

AU - Heo, Jeong

AU - Jeong, Sook Hyang

AU - Lee, Jeong Hoon

AU - Nakayama, Nobuaki

AU - Mochida, Satoshi

AU - Ido, Akio

AU - Tsubouchi, Hirohito

AU - Takikawa, Hazime

AU - Shalimar,

AU - Acharya, Subrat Kumar

AU - Bernal, William

AU - O’Grady, John

AU - Kim, Yoon Jun

N1 - Funding Information: Received February 7, 2018; accepted August 20, 2018. Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.30262/suppinfo. Supported by a grant from the Korean Association for the Study of the Liver. *These authors contributed equally to this work. © 2018 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.30262 Potential conflict of interest: Dr. Mochida is on the speakers’ bureau and received grants from AbbVie GK, Bristol-Myers Squibb, Toray, MSD K.K., and Sumitomo Dainippon. He is on the speakers’ bureau for Ajinomoto and Gilead. He received grants from A2 Healthcare, Chugai, and Eisai. Funding Information: The authors extend their gratitude to the investigators in each center who participated in this study: Dong Hyun Lee, Seung Hyun Ma (Seoul National University); Hee Yeon Kim, Jung Min Bae (Catholic University); Nae-Yun Heo (Inje University); Chang Hyeon Seock, Jihyun An (University of Ulsan); Hana Park, Mi Na Kim (CHA University); Jin Hee Lee, Won Sohn, Ju-Yeon Cho (Sungkyunkwan University); Weiguang Xu (Ajou?University); Chang Hun Lee (Chonbuk National University); Yang Jae Yoo, Chang Ho Jung (Korea?University); Young Oh Kweon, Yu Rim Lee (Kyungpook National University); Soon Koo Baik (Yonsei?University); Jae Young Lee (Yeungnam?University); Oh Sang Kwon, Hyunhwa Yoon (Gachon University); Ki Deok Yoo, Tae?Yeob Kim (Hanyang University); and Hyun Young Woo (Pusan National University). Publisher Copyright: © 2018 by the American Association for the Study of Liver Diseases.

PY - 2019/8

Y1 - 2019/8

N2 - Acute liver failure (ALF) caused by hepatitis A is a rare but fatal disease. Here, we developed a model to predict outcome in patients with ALF caused by hepatitis A. The derivation set consisted of 294 patients diagnosed with hepatitis A–related ALF (ALFA) from Korea, and a validation set of 56 patients from Japan, India, and United Kingdom. Using a multivariate proportional hazard model, a risk-prediction model (ALFA score) consisting of age, international normalized ratio, bilirubin, ammonia, creatinine, and hemoglobin levels acquired on the day of ALF diagnosis was developed. The ALFA score showed the highest discrimination in the prediction of liver transplant or death at 1 month (c-statistic, 0.87; 95% confidence interval [CI], 0.84-0.92) versus King’s College criteria (KCC; c-statistic, 0.56; 95% CI, 0.53-0.59), U.S. Acute Liver Failure Study Group index specific for hepatitis A virus (HAV-ALFSG; c-statistic, 0.70; 95% CI, 0.65-0.76), the new ALFSG index (c-statistic, 0.79; 95% CI, 0.74-0.84), Model for End-Stage Liver Disease (MELD; c-statistic, 0.79; 95% CI, 0.74-0.84), and MELD including sodium (MELD-Na; c-statistic, 0.78; 95% CI, 0.73-0.84) in the derivation set (all P < 0.01). In the validation set, the performance of the ALFA score (c-statistic, 0.84; 95% CI, 0.74-0.94) was significantly better than that of KCC (c-statistic, 0.65; 95% CI, 0.52-0.79), MELD (c-statistic, 0.74; 95% CI, 0.61-0.87), and MELD-Na (c-statistic, 0.72; 95% CI, 0.58-0.85) (all P < 0.05), and better, but not statistically significant, than that of the HAV-ALFSG (c-statistic, 0.76; 95% CI, 0.61-0.90; P = 0.28) and new ALFSG indices (c-statistic, 0.79; 95% CI, 0.65-0.93; P = 0.41). The model was well-calibrated in both sets. Conclusion: Our disease-specific score provides refined prediction of outcome in patients with ALF caused by hepatitis A.

AB - Acute liver failure (ALF) caused by hepatitis A is a rare but fatal disease. Here, we developed a model to predict outcome in patients with ALF caused by hepatitis A. The derivation set consisted of 294 patients diagnosed with hepatitis A–related ALF (ALFA) from Korea, and a validation set of 56 patients from Japan, India, and United Kingdom. Using a multivariate proportional hazard model, a risk-prediction model (ALFA score) consisting of age, international normalized ratio, bilirubin, ammonia, creatinine, and hemoglobin levels acquired on the day of ALF diagnosis was developed. The ALFA score showed the highest discrimination in the prediction of liver transplant or death at 1 month (c-statistic, 0.87; 95% confidence interval [CI], 0.84-0.92) versus King’s College criteria (KCC; c-statistic, 0.56; 95% CI, 0.53-0.59), U.S. Acute Liver Failure Study Group index specific for hepatitis A virus (HAV-ALFSG; c-statistic, 0.70; 95% CI, 0.65-0.76), the new ALFSG index (c-statistic, 0.79; 95% CI, 0.74-0.84), Model for End-Stage Liver Disease (MELD; c-statistic, 0.79; 95% CI, 0.74-0.84), and MELD including sodium (MELD-Na; c-statistic, 0.78; 95% CI, 0.73-0.84) in the derivation set (all P < 0.01). In the validation set, the performance of the ALFA score (c-statistic, 0.84; 95% CI, 0.74-0.94) was significantly better than that of KCC (c-statistic, 0.65; 95% CI, 0.52-0.79), MELD (c-statistic, 0.74; 95% CI, 0.61-0.87), and MELD-Na (c-statistic, 0.72; 95% CI, 0.58-0.85) (all P < 0.05), and better, but not statistically significant, than that of the HAV-ALFSG (c-statistic, 0.76; 95% CI, 0.61-0.90; P = 0.28) and new ALFSG indices (c-statistic, 0.79; 95% CI, 0.65-0.93; P = 0.41). The model was well-calibrated in both sets. Conclusion: Our disease-specific score provides refined prediction of outcome in patients with ALF caused by hepatitis A.

UR - http://www.scopus.com/inward/record.url?scp=85061941912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061941912&partnerID=8YFLogxK

U2 - 10.1002/hep.30262

DO - 10.1002/hep.30262

M3 - Article

C2 - 30194739

AN - SCOPUS:85061941912

SN - 0270-9139

VL - 70

SP - 621

EP - 629

JO - Hepatology

JF - Hepatology

IS - 2

ER -

A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A–Related Acute Liver Failure

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this